Patients were aged 8 weeks through 23 months. Points represent the percentage of patients with bronchiolitis actively monitored with continuous pulse oximetry, measured using direct observation. The dotted blue line indicates overall percentage across all hospitals and the shaded area represents the 95% CI. The risk-standardized percentage for each hospital is the ratio of the predicted to expected use percentages multiplied by the overall percentage across all hospitals. Hospitals are ordered by risk-standardized percentage of patients monitored.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Bonafide CP, Xiao R, Brady PW, et al. Prevalence of Continuous Pulse Oximetry Monitoring in Hospitalized Children With Bronchiolitis Not Requiring Supplemental Oxygen. JAMA. 2020;323(15):1467–1477. doi:10.1001/jama.2020.2998
What percentage of children hospitalized with viral bronchiolitis who are not receiving any supplemental oxygen are continuously monitored with pulse oximetry?
In this cross-sectional study that included 56 hospitals and 3612 patient observations of children hospitalized with bronchiolitis without receipt of supplemental oxygen, pulse oximetry use ranged from 2% to 92%, with a mean of 46%.
Continuous pulse oximetry monitoring among a sample of hospitalized children with bronchiolitis but without an apparent indication for its use had high prevalence.
US national guidelines discourage the use of continuous pulse oximetry monitoring in hospitalized children with bronchiolitis who do not require supplemental oxygen.
Measure continuous pulse oximetry use in children with bronchiolitis.
Design, Setting, and Participants
A multicenter cross-sectional study was performed in pediatric wards in 56 US and Canadian hospitals in the Pediatric Research in Inpatient Settings Network from December 1, 2018, through March 31, 2019. Participants included a convenience sample of patients aged 8 weeks through 23 months with bronchiolitis who were not receiving active supplemental oxygen administration. Patients with extreme prematurity, cyanotic congenital heart disease, pulmonary hypertension, home respiratory support, neuromuscular disease, immunodeficiency, or cancer were excluded.
Hospitalization with bronchiolitis without active supplemental oxygen administration.
Main Outcomes and Measures
The primary outcome, receipt of continuous pulse oximetry, was measured using direct observation. Continuous pulse oximetry use percentages were risk standardized using the following variables: nighttime (11 pm to 7 am), age combined with preterm birth, time after weaning from supplemental oxygen or flow, apnea or cyanosis during the present illness, neurologic impairment, and presence of an enteral feeding tube.
The sample included 3612 patient observations in 33 freestanding children's hospitals, 14 children's hospitals within hospitals, and 9 community hospitals. In the sample, 59% were male, 56% were white, and 15% were black; 48% were aged 8 weeks through 5 months, 28% were aged 6 through 11 months, 16% were aged 12 through 17 months, and 9% were aged 18 through 23 months. The overall continuous pulse oximetry monitoring use percentage in these patients, none of whom were receiving any supplemental oxygen or nasal cannula flow, was 46% (95% CI, 40%-53%). Hospital-level unadjusted continuous pulse oximetry use ranged from 2% to 92%. After risk standardization, use ranged from 6% to 82%. Intraclass correlation coefficient suggested that 27% (95% CI, 19%-36%) of observed variation was attributable to unmeasured hospital-level factors.
Conclusions and Relevance
In a convenience sample of children hospitalized with bronchiolitis who were not receiving active supplemental oxygen administration, monitoring with continuous pulse oximetry was frequent and varied widely among hospitals. Because of the apparent absence of a guideline- or evidence-based indication for continuous monitoring in this population, this practice may represent overuse.
The implementation of continuous pulse oximetry (Spo2) monitoring has enabled timely detection of oxygen desaturation and improved outcomes in operating rooms1 and other high-risk settings2 over the past 50 years. Continuous monitoring use has since expanded to hospital wards without supporting evidence of benefit, likely because of perceptions that it improves safety with little downside.3
Acute viral bronchiolitis is the leading cause of infant hospitalization.4 Bronchiolitis hospital care is primarily supportive, including nasopharyngeal suctioning, nasogastric or intravenous fluids, and supplemental oxygen. Continuous Spo2 monitoring in children with bronchiolitis who do not require supplemental oxygen has been recognized as a form of medical overuse.5-7
Risks associated with continuous Spo2 monitoring in children with bronchiolitis include prolonged length of stay8-11; increased costs attributable to delayed discharge, supplemental oxygen, and oximeter probes12; and potential for iatrogenic harm.13 Monitor alarms also contribute to alarm fatigue among nurses, which is associated with delays in alarm response time.14,15
Appropriate use of continuous Spo2 monitoring in children with bronchiolitis is guided by an American Academy of Pediatrics (AAP) Clinical Practice Guideline5 and Society of Hospital Medicine Choosing Wisely recommendations.6 The American Academy of Pediatrics guideline states that “Clinicians may choose not to use continuous pulse oximetry for children with a diagnosis of bronchiolitis.” The Choosing Wisely recommendations state “Do not use continuous pulse oximetry routinely in children with acute respiratory illness unless they are on supplemental oxygen.”6
The primary objective of this study was to determine the extent of continuous Spo2 monitoring in a population in whom continuous monitoring is not indicated: hospitalized children with bronchiolitis who do not require supplemental oxygen. The primary hypothesis was that continuous Spo2 monitoring use would exceed 30% in the population specified above across sites. The 30% cut point was selected as a guide to inform the decision to subsequently perform a deimplementation trial.
We performed a multicenter cross-sectional study using in-person observation to sample the practice of continuous Spo2 monitoring during bronchiolitis season (December 1, 2018, through March 31, 2019). An overview of this study’s protocol and the projects that will follow was previously published.16 The institutional review board at Children’s Hospital of Philadelphia approved the study, and the remaining US sites established reliance agreements with the reviewing institutional review boards. Research ethics boards at the University of Calgary and The Hospital for Sick Children also reviewed and approved the study. All sites granted waivers of consent, assent, parental permission, and Health Insurance Portability and Accountability Act authorization.
We performed this study in 56 US and Canadian hospitals in the Pediatric Research in Inpatient Settings Network, an independent, hospital-based research network that aims to improve the health of and health care delivery to hospitalized children and their families. Member hospitals were categorized as freestanding children's hospitals (hospitals devoted entirely to the care of children that include a full range of pediatric subspecialty services), children's hospitals within hospitals (general medical hospitals that care mainly for adult patients and include a pediatric department offering a full range of pediatric subspecialty services), and community hospitals (general medical centers that care mainly for adult patients and include a pediatric department offering limited or no pediatric subspecialty services). We performed observations only of acute care pediatric inpatient units not classified as intensive care.
We included patients aged 8 weeks through 23 months. Eligible patients had an active primary diagnosis of bronchiolitis in the hospital chart and were not receiving any supplemental oxygen or nasal cannula flow (even with room air [21% fraction of inspired oxygen]) at the time of data collection. Although the majority of children with bronchiolitis receive supplemental oxygen at some point during their hospital admission, some require only supportive care for respiratory distress (eg, frequent nasal suctioning) or feeding difficulties (eg, intravenous fluids or nasogastric feedings).17 Included patients were cared for by generalist services. We excluded patients documented as having experienced premature or preterm birth without a numeric gestational age listed and those with documented extreme prematurity (<28 weeks’ gestation), cyanotic congenital heart disease, pulmonary hypertension, home oxygen or positive pressure ventilation requirement, tracheostomy, neuromuscular disease, immunodeficiency, or cancer.
Staff at each hospital performed observational rounds during the study period by walking to the bedside of each patient who met the inclusion criteria outlined above. Investigators determined the continuous monitoring status of the patients based on visual confirmation of waveforms and data displayed on the bedside monitor. Each site principal investigator used convenience sampling based on the availability of their data collection team to determine on which dates to perform observational rounds. We restricted observational rounds to occur only during certain hours, designated as “daytime” (10 am to 5 pm) or “nighttime” (11 pm to 7 am). We asked sites to aim to collect at least 60 observations during the bronchiolitis season, targeting approximately 50% of observations during nighttime hours. Weekends were not specifically targeted for data collection. The end cutoff of daytime hours was extended from 4 pm (as in the original protocol16) to 5 pm at the request of site principal investigators prior to the start of data collection to increase feasibility.
Although we did not collect patient identifiers, we required that each observational rounds data collection session be separated by at least 36 hours to limit within-patient repeated measures, given that the median length of stay for bronchiolitis is 2 days.18
Following the in-person data collection, investigators reviewed patients’ charts for demographic and clinical information, including age; gestational age; previous respiratory support during the same hospitalization; presence of feeding tube; apnea or cyanosis during the present illness; prior intensive care unit stay during the present hospitalization; and the presence of conditions associated with neurologic impairment. Patient family-reported race and ethnicity were abstracted from charts in categories defined by the Standards for the Classification of Federal Data on Race and Ethnicity, in compliance with National Institutes of Health inclusion reporting policies.19 In addition to reporting, we planned to analyze race and ethnicity as variables possibly associated with continuous Spo2 monitoring, which could suggest important disparities in care based on race or ethnicity.
We estimated the frequency of within-patient repeated measures by first generating a patient phenotype variable for each unique combination of hospital, unit, age category, gestational age category, race, ethnicity, sex, presence of gastrostomy, and neurologic impairment. Based on bronchiolitis length of stay data from a randomized trial,12 we considered observations of the same patient phenotype that were separated by less than 4 days (approximately the 75th percentile of length of stay in the trial’s usual care group) to possibly represent the same patient.
Because of the straightforward approach to data collection, with basic elements collected from the chart combined with in-person direct observation of monitoring, we expected only trivial amounts of missing data. However, we anticipated missing numeric gestational age documentation in some patients and designed the data collection form to accommodate this issue. If a numeric gestational age was not listed in the chart, the data collector reviewed the chart for qualitative descriptions of the patient as “full term,” “premature,” or “preterm.” Patients described as premature or preterm in the absence of a documented gestational age were assumed to be born prior to 28 weeks and were excluded. Those described as full term or without a qualitative description of gestational age were included. In the analysis, we dichotomized included patients as preterm (28 0/7 to 33 6/7 weeks documented in the chart) or not preterm. We did not perform imputation or use any other methods to replace missing data with values.
We calculated the unadjusted observed continuous Spo2 monitoring use percentage for each hospital as a simple percentage of the total number of observations during which patients were continuously monitored divided by the total number of observations performed at that hospital, comprised exclusively of patients not receiving any supplemental oxygen or nasal cannula flow. We estimated the 95% CI of the unadjusted monitoring percentage accounting for clustering at the hospital level using linear regression with a sandwich estimator for the standard errors allowing for intrahospital correlation (Stata “regress” command with “vce cluster” option). We performed a 1-sample test of this percentage against the hypothesized percentage of 30%, specifying a conservative intraclass correlation of 40% to account for the hospital-level clustering (Stata “prtest” command with “cluster” and “rho” options).
We then examined the bivariable associations of the chart-abstracted demographic and clinical covariates listed above with continuous monitoring use using fixed-effects logistic regression. Given that gestational age and chronological age are often considered in combination when thinking about risk in clinical practice, we used dichotomous preterm status and categorical chronological age jointly as an interaction term in all models (categories shown in Table 1).
We also performed multivariable analyses to compare hospitals’ monitoring percentages in a standardized way, accounting for differences in the patient-level variables potentially associated with monitoring. The purpose of this risk standardization was to approximate what we would have found if we hospitalized a similar cohort of infants in each of the hospitals and to permit identification of statistical outlier hospitals. We chose this approach because we anticipated that patient-level factors associated with use would differ between sites due to site-level differences in patient populations with different degrees of risk20-23 and differences in sampling. To do this, we used methods developed for the Centers for Medicare & Medicaid Services (CMS) for public reporting of hospital quality based on administrative data.24,25 These methods adjust for case-mix differences among hospitals using patient-level factors, thus permitting comparison of hospital performance.25 This approach also assumes that there are underlying differences between hospitals, allowing us to distinguish within-hospital variation from between-hospital variation in continuous Spo2 monitoring use.26
For each hospital, we first calculated the expected continuous Spo2 monitoring use percentage given the hospital-specific differences in case mix using patient-level variables. We used a fixed-effects multivariable logistic regression model that included the covariates that met the prespecified criteria of having composite P values less than .20 for being continuously Spo2 monitored in the model described above. We retained variables in this model with P values that remained less than .20 when included in the multivariable model. This expected use percentage estimates the monitoring percentage if the set of patients observed at this hospital were treated at the average hospital.26
We then calculated the predicted use percentage for each hospital by incorporating the hospital-specific random effect into the multivariable fixed-effects model (resulting in the final mixed-effects regression model that accounts for hospital-level clustering). We computed a risk-standardized monitoring percentage for each hospital as the ratio of the predicted to expected use percentages multiplied by the unadjusted overall percentage across all hospitals. We constructed percentile-based 95% CIs for the risk-standardized percentages of each hospital based on 1000 samples.25,26 We considered hospitals to be “statistical high-use outliers” if the lower bound of the 95% CI was higher than the overall observed monitoring percentage and “statistical low-use outliers” if the upper bound of the 95% CI was lower than the overall percentage.25 We excluded hospitals that submitted fewer than 20 observations from the hospital comparisons.
We used data collection forms designed in REDCap and hosted centrally at Children’s Hospital of Philadelphia.27 We used SAS software version 9.4 (SAS Institute Inc) and Stata version 15.1 (StataCorp LLC) for analysis. We used publicly available statistical code in the 2018 CMS Mortality Measures SAS pack to calculate the risk-standardized monitoring percentage for each hospital and to construct percentile-based 95% CIs. Statistical significance was defined as 2-sided P < .05.
We conducted 3612 patient observations in 33 freestanding children's hospitals, 14 children's hospitals within hospitals, and 9 community hospitals during the 4-month study period (Figure 1). Seven hospitals collected fewer than 20 observations and were excluded from hospital comparisons. Of the 49 hospitals with at least 20 observations, the median (interquartile range) number of observations per hospital was 63 (50-89). Two hospitals were in Canada and the remainder were in the US.
The study population of children with bronchiolitis was 59% male, 56% white, 15% black, and 21% Hispanic or Latino; 48% were aged 8 weeks through 5 months, 28% were aged 6 through 11 months, 16% were aged 12 through 17 months, and 9% were aged 18 through 23 months. Overall, 66% of patients received supplemental oxygen or flow earlier during their current admission. Investigators performed 43% of observations during nighttime hours (11 pm to 7 am). Ten percent of observations had another observation of the same patient phenotype in the preceding 4 days. Other patient characteristics are included in Table 1.
In the included patients with bronchiolitis, none of whom were receiving any supplemental oxygen or nasal cannula flow at the time of data collection, the overall percentage with continuous Spo2 monitoring use, accounting for clustering at the hospital level, was 46% ([95% CI, 40%-53%]; 2-sided P < .001), rejecting the null hypothesis. Of the 49 hospitals that collected at least 20 observations, the hospital-level unadjusted continuous Spo2 monitoring use percentages ranged from 2% to 79% for the 30 freestanding children’s hospitals (hospital-level median, 40%), from 7% to 92% for the 12 children’s hospitals within hospitals (hospital-level median, 58%), and from 22% to 77% for the 7 community hospitals (hospital-level median, 48%).
In unadjusted fixed-effects analyses, the following variables met the prespecified criteria to be included in the multivariable model: nighttime, age combined with preterm birth, time after weaning from supplemental oxygen or flow, documented history of apnea or cyanosis during the present illness, neurologic impairment, and presence of an enteral feeding tube (Table 2). Ethnicity met initial criteria to enter the multivariable model based on having a bivariable association P value less than .20 but was eliminated from the multivariable model for having a composite P value of 0.34.
In the final adjusted mixed-effects regression analysis (Table 2), the following variables were significantly associated with continuous Spo2 monitoring: age combined with preterm birth (eg, odds ratio [OR] of children aged 8 wk through 5 mo and born preterm, 2.58 [95% CI, 1.65-4.02]; P < .001 relative to reference group of children aged 18 through 23 mo and not born preterm), time since weaning from supplemental oxygen or flow (eg, OR of patients who had not received supplemental oxygen for the past 2-<4 h, 5.55 [95% CI, 3.91-7.89]; P < .001 relative to reference group of patients who never received supplemental oxygen or flow), documented history of apnea or cyanosis during the present illness (OR, 1.40 [95% CI, 1.01-1.93]; P = .041), presence of an enteral feeding tube (OR, 1.98 [95% CI, 1.46-2.67]; P < .001), and nighttime (OR, 2.07 [95% CI, 1.76-2.43]; P < .001).
Risk-standardized percentages of continuous Spo2 monitoring use ranged from 6% to 82% (Figure 2). Seventeen hospitals were statistical high-use outliers (9 freestanding children’s hospitals, 6 children's hospitals within hospitals, and 2 community hospitals) and 10 hospitals were statistical low-use outliers (6 freestanding children’s hospitals, 2 children's hospitals within hospitals, and 2 community hospitals). The adjusted model’s intraclass correlation coefficient suggested that 27% (95% CI, 19%-36%) of the observed variation was attributable to unmeasured hospital level factors.
In this multicenter cross-sectional study involving a convenience sample of children hospitalized with bronchiolitis who were not actively receiving supplemental oxygen, continuous Spo2 monitoring occurred frequently, and this practice varied widely among hospitals.
To our knowledge, this is the first study to measure continuous Spo2 monitoring use in patients with bronchiolitis using direct observation. In a multicenter pediatric quality improvement collaborative, use of continuous Spo2 monitoring in patients with bronchiolitis not receiving supplemental oxygen was assumed if an active monitoring order existed at the time the patient was discharged, but the investigators did not measure the use of continuous Spo2 monitoring at other points in the hospitalization.28 A single-center quality improvement project targeting length of stay reduction in individuals with bronchiolitis also used orders as a measure of continuous vs intermittent Spo2 monitoring practice.11 Neither project validated the presence of orders against actual monitoring at the bedside. A second single-center quality improvement project identified continuous Spo2 monitoring status in children with wheezing by examining monitor data that was directly integrated into the electronic health record to quantify time undergoing continuous Spo2 monitoring after patients were weaned to receive albuterol treatments every 2 hours or off supplemental oxygen to room air.29
The current study provides evidence suggesting continuous Spo2 monitoring overuse in children with bronchiolitis, despite national guidelines discouraging its use in this population, and has additional broader implications. Recent estimates suggested that the total cost of waste from overtreatment or low-value care in the US ranges from $75.7 billion to $101.2 billion.30 Since the publication of a landmark 2010 article challenging medical specialty societies to create “top 5” lists of frequently ordered tests or treatments that provide little benefit,31 attention to minimizing the use of low-value, ineffective, or unproven health care practices increased.32-34 There is an emerging science of deimplementation, the systematic, structured reduction or elimination of low-value care practices, that may inform efforts to reduce monitoring overuse.35,36 This project represents essential first steps in deimplementing an overused low-value care practice: measuring “baseline” or “usual care” practices, measuring contextual contributors to overuse, and identifying outlier sites to begin the process of assessing barriers and facilitators to deimplementation.37
This study has several limitations. First, it is possible that the convenience sampling approach resulted in a sample not representative of the entire population of stable patients with bronchiolitis. This pragmatic approach was necessary to include a diverse set of hospitals, many of which had limited resources for data collection. However, because data collectors were physicians and nurses at some hospitals, it is possible that during very high-census days in the hospital, those individuals were required to provide direct patient care and thus were unavailable to collect data. If monitor use was more prevalent during high-census days, this convenience sampling approach would have biased our findings toward the null. As physiologic monitoring data become more easily accessible, it is likely that future studies will determine continuous monitoring status using electronic health record data only, eliminating the need for in-person data collection. Second, freestanding children’s hospitals were overrepresented in the sample. There is a need to include more community hospitals in research because less than 30% of pediatric hospitalizations in the US occur in freestanding children’s hospitals.38 Third, the relationships of other hospital-level factors (eg, presence of clinical pathways [which have been shown to improve quality of care and reduce overuse in pediatric asthma],39 characteristics of the nurse work environment associated with patient safety40) and other patient-level factors (eg, work of breathing, respiratory rate, other comorbidities) were not analyzed in this study but might contribute to continuous Spo2 monitoring use. Fourth, because observers only visited each bedside once during data collection rounds, it is possible that some patients were classified as being continuously monitored at time points when they were actually having intermittent vital sign measurements. Fifth, no data were available to determine whether actions were taken to change monitoring practice during the study period in response to occurrence of the observational data collection rounds. Actively changing individual practice was discouraged by requiring that the data collectors not be simultaneously involved in the care of the patients whose data were being collected. Actively changing group practice (eg, at the unit or department level) in response to feedback of continuous Spo2 use results was prevented by hosting and managing the REDCap database centrally. Individual sites had data entry access only and could not generate reports or download their raw data. Continuous Spo2 use data were shared with hospitals after the data collection period ended. Sixth, the statistical analysis accounted for clustering at the hospital level but could not account for patient, nurse, or physician clustering due to limitations of the data collected.
In a convenience sample of children hospitalized with bronchiolitis not receiving active supplemental oxygen administration, continuous Spo2 monitoring was frequent and varied widely among hospitals. Because of the apparent absence of a guideline- or evidence-based indication for continuous monitoring in this population, this practice may represent overuse.
Corresponding Author: Christopher P. Bonafide, MD, MSCE, Research Director for Pediatric Hospital Medicine, CHOP Buerger Center for Advanced Pediatric Care, 3500 Civic Center Blvd, Philadelphia, PA 19104 (email@example.com).
Accepted for Publication: February 24, 2020.
Author Contributions: Drs Bonafide and Xiao had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Bonafide, Brady, Landrigan, Brent, Wolk, Bettencourt, McLeod, Barg, Beidas, Schondelmeyer.
Acquisition, analysis, or interpretation of data: Bonafide, Xiao, Brady, McLeod, Barg, Schondelmeyer.
Drafting of the manuscript: Bonafide, Xiao, Bettencourt, Beidas.
Critical revision of the manuscript for important intellectual content: Bonafide, Xiao, Brady, Landrigan, Brent, Wolk, McLeod, Barg, Beidas, Schondelmeyer.
Statistical analysis: Bonafide, Xiao.
Obtained funding: Bonafide, Landrigan, Barg, Schondelmeyer.
Administrative, technical, or material support: Landrigan, Brent, Bettencourt, McLeod, Schondelmeyer.
Supervision: Landrigan, McLeod, Barg.
Other - implementation science aspects of the project: Wolk.
Conflict of Interest Disclosures: Dr McLeod reported participating in this project when she was a faculty member at Children’s Hospital Colorado and being currently employed by Array BioPharma, where her work is unrelated to this project. Dr Bonafide reported receiving grants from the National Institutes of Health/National Heart, Lung, and Blood Institute during the conduct of the study and grants from the Agency for Healthcare Research and Quality and National Science Foundation outside the submitted work. Dr Landrigan reported receiving personal fees having equity in I-PASS Institute outside the submitted work and receiving monetary awards, honoraria, and travel reimbursement from multiple academic and professional organizations for teaching and consulting on sleep deprivation, physician performance, handoffs, and safety and serving as an expert witness in cases regarding patient safety, handoffs, and sleep deprivation. Ms Brent reported receiving grants from the National Heart, Lung, and Blood Institute during the conduct of the study. Dr Wolk reported receiving grants from the National Institutes of Health during the conduct of the study and grants from the National Institutes of Health, Institute of Education Science, and Health Resources and Services outside the submitted work. Dr Bettencourt reported receiving grants from the National Heart, Lung, and Blood Institute during the conduct of the study. Dr Beidas reported receiving grants from the National Heart, Lung, and Blood Institute during the conduct of the study and royalties from Oxford University Press; personal fees from Merck Sharpe & Dohme, Camden Coalition of Healthcare Providers, and the Oregon Social Learning Center; and awards from the American Psychological Association and the Association for Behavioral and Cognitive Therapies outside the submitted work. Dr Schondelmeyer reported receiving grants from the National Heart, Lung, and Blood Institute and grants from Agency for Healthcare Research and Quality during the conduct of the study and grants from the Association for the Advancement of Medical Instrumentation Foundation outside the submitted work. No other disclosures were reported.
Funding/Support: Research reported in this publication was supported by a cooperative agreement awarded to Dr Bonafide from the National Institutes of Health/National Heart, Lung, and Blood Institute under award number U01HL143475.
Role of the Funder/Sponsor: As a cooperative agreement, National Institutes of Health scientists participated in study conference calls and provided ongoing feedback on the conduct and findings of the study. The funding organization had no role in the design of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Group Information: We thank the PRIS Network collaborators for their major contributions to data collection: Akron Children’s Hospital: Jaclyn Urquiola Sorzano, DO; Karuna Ramcharran, MPH; Prabi Rajbhandari, MD, FAAP; Thomas Mike, MD. Alberta Children’s Hospital: Christopher Andrews, BSc (H), MD, FRCP(C); Lindsay Long, BSc, MD, FRCP(C); Michelle Bailey, BSc (H), MSc, MD, FRCP(C). American Family Children’s Hospital: Kristin Shadman, MD; Rhonda Yngsdal-Krenz, MBA; Sarah MacKay, MD. Ann & Robert H. Lurie Children’s Hospital of Chicago: Kate Lucey, MD, MS; Kristin Van Genderen, MD; M. Katherine Stone, MD, MPH; Michael Spewak, MD; Victoria A. Rodriguez, MD; Waheeda Samady, MD, MSCI. Antelope Valley Hospital: Della Archambo, MSN, RN-BC; Lynne Ellison, DO, MT. Boston Children’s Hospital: Deanna Chieco, MD; Elizabeth Pingree, MD; Patricia Stoeck, MD. C.S. Mott Children’s Hospital: Hiral Mehta, MD; Katrina Foo, MD; Kimberly Monroe, MD, MS; Luzum Matthew, MD, MPH; Mayya Malakh, MD; Nora Biary, MD; Rebekah Shaw, MD. Children’s Hospital & Medical Center Omaha: Chelsea Bloom Anderson, MD; Gregory Johnson, MD; Jacquie Hanks, DNP; Jodi Cantrel, MD; Katherine MacKrell, MD; Melissa England, MD; Russell McCulloh, MD; Sharon Stoolman, MD; Sheilah Snyder, MD. Children’s Hospital at Montefiore: Alyssa Silver, MD; Priya Jain, MD. Children’s Hospital Colorado: Amy Tyler, MD; Michael Tchou, MD. Children’s Hospital Los Angeles: Christopher Russell, MD, MS; Maria Santos, MD; Phillip Abarca, BA; Susan Wu, MD; Vivian Lee, MD. Children’s Hospital New Orleans: Amanda Messer, MD; George Hescock, MD. Children’s Hospital of Oklahoma: Monique Naifeh, MD, MPH; Rachna May, MD; Stephanie Deleon, MD. Children’s Hospital of Philadelphia: Laura El-Hage, MD; Padmavathy Parthasarathy, MD; Stan Oliveira, RN, BSN. Children’s Hospital of Richmond at Virginia Commonwealth University: Amy Spinella, NP; Christine Sirota, NP; Hadi Anwar, MD; Jennifer Schrecengost, NP. Children’s Hospital of The King’s Daughters: Bradley Sieckman, MD; Hope Breckenridge, MSN; Judith Roberts, MSN, RN; Kyrie Shomaker, MD; Megan Brinkley, MSN; Mishi Bhushan, MD, MPH. Children’s Medical Center Dallas: Caitlin Layton, BSN, RN; Courtney Solomon, MD; Danielle Dukellis, MD; Hailee Scoggins, BSN; Mayra Garcia, DNP, RN, PCNS-BC. Children’s Mercy Kansas City: Amita Amonker, MD; Ashley Daly, MD; Kathleen Berg, MD; Matthew Johnson, MD. Children’s National Medical Center: Lynsey Watry, MD; Margaret Rush, MD, MSHS; Tamara Gayle, MD, MEd; Tina Halley, MD. CHOP Care Network at Virtua: Rashida Pittalwala, MD; Shraddha Mittal, MD. Cincinnati Children’s Hospital Medical Center: Sarah Ferris, BA. Cohen Children’s Medical Center: Alexandra Kilinsky, DO; Alyssa Churchill, MD; Ann Le, DO; Erin P. Allmer, MD; Hayley Wolfgruber, MD; Kimberly Lau, MD; Kriti Gupta, MD; Nicole Irgens-Moller, MD. Connecticut Children’s Medical Center: Amy Blodgett, MD; Aseel Dabbagh, DO; Chelsea Lepus, DO; Danielle Klima, DO; Ilana Waynik, MD; Owen Kahn, MD. Cook Children’s Medical Center: Amy Turner, NP; Karen Schultz, MD; Stacey VanVliet, MD. Cox Medical Center South: Jessica Sears, MD; Kayce Morton, DO. Dayton Children’s Hospital: Beth Sullivan, MD; Merrilee Cox, MD. Diamond Children's Medical Center: Adam Walpert, MD; Chan Lowe, MD; Geetha Gopalakrishnan, MD; Janet Lau, MD; Jasna Seserinac, MD; Melissa Cox, DO; Rachel Cramton, MD. Grand View Hospital: Andrew Chu, MD; Kathleen Shafer, RN; Krista Zehr, RN; Mary Nicolai, RN; Sheila Knerr, MD; Valarie Polk, RN. Hassenfeld Children’s Hospital at NYU Langone: Jasmine Gadhavi, MD. Inova Children’s Hospital: Alexandru Firan, MD; Carolina Saldarriaga Perez, MD; Meredith Carter, MD, MEd. Lucile Packard Children’s Hospital Stanford: Alan Schroeder, MD; Kevin Chi, MD. Mary Washington Hospital: Allison Markowsky, MD, MSHS; Katherine Donowitz, MD; Nailah Coleman, MD; Summer Peters, DO. MUSC Children’s Hospital: Ronald Teufel II, MD, MSCR; Sasha Wee, MD. Nationwide Children’s Hospital: Allison Heacock, MD; Kimberly Tartaglia, MD; Matthew Emery, MD; Michael Perry, MD; Nancy Liao, MD; Ryan Bode, MD; Stephanie Kwon, MD. Nemours/A.I. duPont Hospital for Children: Samuel Stubblefield, MD. Poudre Valley Hospital & Medical Center of the Rockies: Elizabeth Ballard, MD. Primary Children’s Hospital: Ashley Dennis, MD; Glen Huff, MD; John Mulcaire-Jones, MD; Karee Nicholson, RN, MSN; Katie Mailey, MD; Robert Willer, DO. Princeton Medical Center: Alicia Brennan, MD; Anupa Dalal, MD; Geetha Lingasubramanian, MD; Joel Krauss, MD; Julianne Prasto, MD; Koel Guha, MD; Marissa Castellano, MD. Riverton Hospital: Glen Huff, MD. Seattle Children’s Hospital: Kaitlyn McQuistion, MD; Sarah Zaman, MD. St Louis Children’s Hospital: Christine Hrach, MD; Erik Hoefgen, MD; Laura Hulteen, MD; Shakila Mathew, MD; Tosin Adeyanju, MD. St Mary’s Hospital: Ann Allen, MD. Texas Children’s Hospital: Imgard Carolina Molleda Castro, MD; Mohammad Ovais Aziz, MD; Mohammed Nassif, MD; Ricardo Quinonez, MD. The Hospital for Sick Children: Amna Hilal, MD; Brie Yama, MD, MSc, MEd (c), FRCPC, FAAP; Brigitte Parisien, MD; Catherine Diskin, MB, BCH, BAO, MRCPI (Paid) MSc; Dana Arafeh, BSc, CAPM; Sanjay Mahant, MD, MSc, FRCPC. Tufts Medical Center Floating Hospital for Children: Elena Aragona, MD, MS; Jana Leary, MD, MS. UCSF Benioff Children’s Hospital Mission Bay: Glenn Rosenbluth, MD; Manisha Israni-Jiang, MD; Matt Pantell, MD, MS. University Hospitals Rainbow Babies and Children’s Hospital: Allayne Stephans, MD; Amanda Lansell, MD. University of Iowa Stead Family Children’s Hospital: Guru Bhoojhawon, MBBS, MD; Katherine Patrick, MD; Kelly Wood, MD; Kristen Sandgren, MD. University of Vermont Children’s Hospital: Leigh-Anne Cioffredi, MD, MPH. UPMC Children’s Hospital of Pittsburgh: Kishore Vellody, MD; Sylvia Choi, MD. Upstate Golisano Children’s Hospital: John Andrake, MD; Melissa Schafer, MD. Valley Children’s Hospital: Angela Veesenmeyer, MD, MPH; Katie Chan-Boeckh, RN; Laura Grant, RN; Nicole Webb, MD. Vanderbilt University Medical Center: Derek Williams, MD, MPH; Emily Datyner, MD; Gregory Plemmons, MD; Jakobi Johnson, BS. Wake Forest Baptist Medical Center: Jeanna Auriemma, MD; John Darby, MD; Nicholas Potisek, MD; Sean Ervin, MD, PhD. WVU Children’s Hospital: Chickajajur Vijay, MD, MBBS; Christy Glass, MSN; Kamakshya Patra, MD; Kudora Maize, MSN, APRN; Meghan Williams, MSN, FNP-C; Travis Kennedy, MSN, APRN, FNP-BC. Yale-New Haven Children’s Hospital: Adam Berkwitt, MD.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Meeting Presentation: Results of this study were presented at the Pediatric Hospital Medicine Annual Meeting; July 26, 2019; Seattle, WA.
Additional Contributions: We thank the Center for Outcomes Research & Evaluation at Yale School of Medicine for sharing the Centers for Medicare & Medicaid Services SAS pack for risk standardization, which is freely available to the public upon request from firstname.lastname@example.org. We acknowledge the National Heart, Lung, and Blood Institute scientists who contributed their expertise to this project as part of the U01 cooperative agreement funding mechanism as federal employees conducting their official job duties: Lora Reineck, MD, MS; Karen Bienstock, MS; and Cheryl Boyce, PhD. We thank Justin Lakkis, BA, a PhD student at the University of Pennsylvania, for his contributions to statistical analysis. He did not receive compensation for his role in the study. We thank the Executive Council of the Pediatric Research in Inpatient Settings Network for their contributions to the early scientific development of this project. The Network assessed a collaborative support fee for access to the hospitals and support of this project.
Create a personal account or sign in to: